Newsbenzinga
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
· Published
Article summary
Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.
An excerpt from the original article.
Comments —
Loading comments…